Closeup on the ADA 2022 Standards of Medical Care | With Prof. Anne Peters

Diabetes Knowledge into Practice Podcast

The 2022 Standards of Medical Care in Diabetes is published every year by the American Diabetes Association to reflect the latest available clinical evidence. The most significant updates this year include a lower age to begin screening for prediabetes and diabetes, an increased emphasis on individualization of treatment, and further recommendations around the use of technologies such as continuous glucose monitoring and treatment of obesity.

To hear more about some of these updates and their rationale, we’re joined by Professor Anne Peters, a member of the ADA’s Professional Practice Committee which reviews and updates the Standards.

By completing this activity you can qualify for 0.25 CME credits. To claim your credits, you must listen to the podcast and successfully pass the post-module assessment at https://diabetes.knowledgeintopractice.com, where you can find all past episodes of the podcast as well as other free CME resources.

References available here

Disclosures:

Prof. Anne Peters disclosures are as follows:

Participation on an advisory board - Abbott Diabetes Care, Astra Zeneca, Eli Lilly, Medscape, Novo Nordisk, ShouTi Inc, Vertex, Zealand

Research support - Abbott Diabetes Care, Dexcom, Insulet

Stock - Teladoc

Stock options - Omada Health

Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

Target Audience

This educational activity is intended for an international audience of non-US and non-UK HCPs.

Funding:

This independent educational activity is supported by an educational grant from Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; Novo Nordisk A/S has had no influence on the content of this education.